Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24353218 | 0.90 | ALDH1A1 (0.46) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL24353318 | 0.88 | ALDH1A1 (0.48) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL24353221 | 0.88 | PDE4A (0.45) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL24353217 | 0.87 | PKM (0.40) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL24353322 | 0.86 | ALDH1A1 (0.46) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL24353182 | 0.85 | ALDH1A1 (0.44) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL18456744 | 0.85 | ALDH1A1 (0.43) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL24353229 | 0.85 | ALDH1A1 (0.43) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL24353215 | 0.84 | ALDH1A1 (0.46) | ALDH1A1HTTLMNAKDM4ETDP1 | |
| SCHEMBL18457051 | 0.84 | ALDH1A1 (0.43) | ALDH1A1HTTLMNAKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312690-B2 | Compounds, compositions, methods for treating diseases, and methods for preparing compounds | UNIVERSITY OF LOUSVILLE RESEARCH FOUNDATION, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312690-B2 | Compounds, compositions, methods for treating diseases, and methods for preparing compounds | VHL, C5, KRAS | ALDH1A1 475/4885HTT 173/4885LMNA 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.